For the six months ended October 31, 2012 and 2011, gross margins for POS were 0 percent and 25 percent, respectively.0 million and $1.2 million for the three months ended October 31, 2012 and 2011, respectively, a loss of $0.2 million, or 17 percent. The reduction in TOS revenues was because of decreased contract bookings in the previous quarters primarily. TOS revenues had been $2.2 million for each of the six month intervals ended October 31, 2012 and 2011.Chen, MD, Ph.D., the firm's Chief Medical Officer, and recommend an equivalent human treatment for ovarian cancers patients is normally feasible. This process is usually early but if we’re able to achieve similar results in human clinical trials with women experiencing ovarian tumor this treatment could significantly change the current standard of care. Related StoriesStudy shows rare HER2 missense mutations usually do not spread breasts cancer on the ownSausages With Antioxidants From Berries TO AVOID CancerMD Anderson research reveals why chemotherapy drugs not effective for many pancreatic cancer patients The business's two medication candidates previously demonstrated substantial reduced tumor growth and progression in pre-clinical testing against 6 aggressive cancers: triple bad breast cancer; primary prostate cancers; prostate bone metastasis; ovarian tumor; melanoma; and glioblastoma.

Children’s hospital thanks a lot Montrealers for abundant gadget donations Every year at The Montreal Children’s Hospital of the McGill University Wellness Centre, we turn to members of the city to help make Christmas unique for the young children who are not sufficiently to go back home for the holidays.